European Commission Grants Final Approval for Arrowhead's APOC3 Inhibitor, Redemlpo
First-in-Class Gene-Unrelated siRNA Therapy for Rare Disease
The European Commission (EC) has granted final approval for Redemlpo (plozasiran), a novel small interfering RNA (siRNA) drug from Arrowhead Pharmaceuticals, for the treatment of familial chylomicronemia syndrome (FCS). This approval marks a significant advancement in patient access, as it is the first therapy authorized for use based solely on clinical diagnostic criteria, regardless of genetic testing confirmation. Redemlpo works by selectively blocking the messenger RNA (mRNA) of apolipoprotein C-III (APOC3) in the liver, thereby reducing triglyceride levels. This mechanism overcomes the limitations of existing standard treatments and offers patients a new therapeutic option.
Significant Triglyceride Reduction Based on Phase 3 PALISADE Study
This approval is based on the robust data from the Phase 3 PALISADE study, which involved patients with rare diseases. In the Redemlpo 25mg dose group, the median triglyceride levels were reduced by 80% compared to placebo at 10 months after treatment. The 50mg dose group also showed a high reduction rate of 78%. Notably, a post-hoc analysis revealed that Redemlpo reduced the risk of acute pancreatitis, a life-threatening complication for FCS patients, by 83% compared to placebo. This finding was a key factor in the regulatory agency's positive review. With its convenient once-quarterly administration, Redemlpo is expected to significantly improve patient compliance.
Competitive Landscape in the APOC3 Target Market
With the European approval of Redemlpo, the global APOC3-targeted therapy market is entering a three-way competition. The existing approved drug, Waylivra, an antisense oligonucleotide (ASO) therapy from Ionis, requires weekly administration and carries the risk of side effects such as thrombocytopenia. In contrast, Tryngolza (olezarsen), Ionis's next-generation drug recently approved in the US and Europe, is administered monthly. Redemlpo's once-quarterly administration offers a convenience advantage. Market research indicates that the global FCS market is expected to grow from $642.5 million in 2024 to $1.16 billion in 2033, and Redemlpo is expected to capture a significant share of this market.
Arrowhead's Independent Commercialization Strategy and Licensing Agreement in Asia
Arrowhead is pursuing a strategy of independently launching Redemlpo in key markets such as the US and Europe to maximize commercial profits. However, to penetrate the Asian market, the company successfully entered into an agreement with Sanofi through its subsidiary, Visirna, in August 2025, granting Sanofi the rights to develop and commercialize Redemlpo in China and other Asian countries. This deal includes an upfront payment of $130 million and milestone payments of $265 million, totaling $395 million. This European approval serves as clear evidence that Arrowhead has evolved from a research and development company into a global commercial-stage biotechnology company.
This European approval is a key milestone that maximizes Arrowhead's potential to gain a leading position in the familial chylomicronemia syndrome (FCS) market, which is projected to grow to approximately $1.16 billion by 2033. The data from the Phase 3 PALISADE study, demonstrating up to an 80% reduction in triglyceride levels and an 83% reduction in the risk of acute pancreatitis, provides a strong clinical competitive advantage. This advantage, combined with the convenience of once-quarterly administration compared to competitors such as Ionis's Tryngolza, will be crucial in securing long-term market share. The $395 million licensing agreement with Sanofi for the Chinese market, along with the retention of exclusive rights in the European market, demonstrates the company's financial stability and global commercial capabilities. In the long term, this success is expected to enhance the value of the pipeline for subsequent indications, such as severe hypertriglyceridemia (sHTG), further increasing its investment appeal.
Source: EMA (ema)